Non-specific inflammatory bowel disease including Crohn’s disease (CD) (Enteritis regionalis) and ulcerative colitis (UC) are characterized by chronic-remitting inflammatory processes of the intestine. Anti-GP2 ELISA determine antibodies to the major antigen of the exocrine pancreas, the membrane-bound pancreatic Glycoprotein 2 (GP2). Antibodies against GP2, in combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA), which is highly prevalent (70 %) in patients with CD and atypical antineutrophil cytoplasmatic antigens (aANCA), mainly found in patients with UC, could be used as a highly specific serological marker for differential diagnosis of CD to UC. Anti-GP2 ELISA is used for the quantitative determination of IgA and IgG antibodies against glycoprotein 2 (GP2) in human serum. Like all other GA Generic Assays’ ELISA assays, the Anti-GP2 ELISA can be implemented on all the most common open ELISA automation systems.